Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

EB-003

From Wikipedia, the free encyclopedia
Pharmaceutical compound
EB-003
Clinical data
Other namesEB003
Drug classNon-hallucinogenicserotonin receptor agonist;Psychoplastogen;Neurostabilogen

EB-003 is a non-hallucinogenicserotonin receptor agonist which is under development for the treatment ofdepressive disorders andanxiety disorders.[1][2][3][4][5] It is atryptamine[1][5] and aderivative of theserotonergic psychedelicdimethyltryptamine (DMT).[3]

The drug acts as anon-selectiveagonist ofserotonin receptors, including of theserotonin5-HT1A,5-HT1B, and5-HT2A receptors.[1][3][4][5] It is not a serotonin5-HT2B receptor agonist.[5][6] EB-003 producespsychoplastogenic effects.[3][4][5] Due to targeting not only the serotonin 5-HT2A receptor but also the serotonin 5-HT1B receptor to influenceneuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer.[3]

EB-003 is being developed by Enveric Biosciences.[1][2] As of February 2025, it is in thepreclinical research stage of development.[1][2] Aphase 1clinical trial is being planned.[1] The drug's exactchemical structure does not yet seem to have been disclosed.[1][5] It has beenpatented, though the patent does not yet appear to have been published.[7]

See also

[edit]

References

[edit]
  1. ^abcdefg"EB-003 - Enveric Biosciences".AdisInsight. 6 February 2025. Retrieved16 February 2025.
  2. ^abc"Delving into the Latest Updates on EB-003(Enveric Biosciences) with Synapse".Synapse. 23 January 2025. Retrieved16 February 2025.
  3. ^abcdeRoberts, Madison (28 August 2025)."AbbVie's $1B Psychedelic Bet: Who's Next in the Neuroplastogen Gold Rush?".Microdose. Retrieved22 October 2025.
  4. ^abc"Pipeline – Enveric Biosciences".Enveric Biosciences. Retrieved16 February 2025.
  5. ^abcdef"Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series".Financial Post. BusinessWire. 28 December 2023. Retrieved16 February 2025.
  6. ^"Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003".ENVB Stock News. 15 October 2024. Retrieved16 February 2025.
  7. ^"Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office".Yahoo Finance. 30 January 2025. Retrieved16 February 2025.
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=EB-003&oldid=1318154388"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp